Novavax, Inc. (NASDAQ:NVAX) Given Consensus Rating of "Hold" by Analysts

Novavax, Inc. (NASDAQ:NVAX - Get Free Report) has been assigned a consensus recommendation of "Hold" from the six brokerages that are currently covering the company, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, two have given a hold recommendation and three have assigned a buy recommendation to the company. The average 1 year target price among brokerages that have issued ratings on the stock in the last year is $17.83.

A number of equities research analysts recently weighed in on the stock. Jefferies Financial Group lowered their price objective on shares of Novavax from $31.00 to $25.00 and set a "buy" rating for the company in a research report on Wednesday, October 16th. B. Riley reaffirmed a "buy" rating and set a $26.00 target price (up from $23.00) on shares of Novavax in a report on Thursday, October 10th. Finally, HC Wainwright reissued a "buy" rating and issued a $19.00 price target on shares of Novavax in a report on Tuesday, December 10th.

Novavax Trading Down 1.5 %

NASDAQ NVAX traded down $0.13 on Tuesday, hitting $8.51. 1,475,572 shares of the stock traded hands, compared to its average volume of 9,158,966. The company has a market capitalization of $1.36 billion, a P/E ratio of -3.77 and a beta of 2.02. The stock has a 50-day moving average of $9.05 and a 200 day moving average of $11.75. Novavax has a twelve month low of $3.53 and a twelve month high of $23.86.

Novavax (NASDAQ:NVAX - Get Free Report) last released its quarterly earnings data on Tuesday, November 12th. The biopharmaceutical company reported ($0.76) EPS for the quarter, topping analysts' consensus estimates of ($0.83) by $0.07. The business had revenue of $84.51 million during the quarter, compared to analyst estimates of $65.80 million. The business's revenue for the quarter was down 54.8% compared to the same quarter last year. During the same period in the prior year, the firm earned ($1.26) EPS. As a group, equities research analysts expect that Novavax will post -1.44 earnings per share for the current year.

Institutional Trading of Novavax

Large investors have recently added to or reduced their stakes in the business. Charles Schwab Investment Management Inc. increased its stake in Novavax by 16.5% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 1,325,508 shares of the biopharmaceutical company's stock valued at $16,741,000 after buying an additional 187,548 shares during the period. Bank of Montreal Can increased its stake in shares of Novavax by 26.7% during the third quarter. Bank of Montreal Can now owns 2,454,325 shares of the biopharmaceutical company's stock valued at $32,643,000 after acquiring an additional 517,727 shares during the period. Shah Capital Management raised its holdings in Novavax by 19.0% during the second quarter. Shah Capital Management now owns 9,662,090 shares of the biopharmaceutical company's stock worth $122,322,000 after purchasing an additional 1,544,263 shares in the last quarter. State Street Corp lifted its position in Novavax by 26.7% in the third quarter. State Street Corp now owns 7,687,951 shares of the biopharmaceutical company's stock worth $97,099,000 after purchasing an additional 1,621,772 shares during the period. Finally, Vontobel Holding Ltd. boosted its stake in Novavax by 110.3% during the 3rd quarter. Vontobel Holding Ltd. now owns 498,532 shares of the biopharmaceutical company's stock valued at $6,296,000 after purchasing an additional 261,464 shares in the last quarter. 53.04% of the stock is currently owned by institutional investors and hedge funds.

About Novavax

Novavax, Inc, a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response.